Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$92.22 0.76 (0.83%) as of 4:30 Fri 4/12


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 17.37(B)
Last Volume: 2,419,825 Avg Vol: 1,397,134
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 96,943 140,707 274,067 630,886
Total Sell Value $8,465,340 $12,662,649 $25,097,267 $59,354,987
Total People Sold 4 4 5 8
Total Sell Transactions 8 12 21 57
End Date 2024-01-14 2023-10-13 2023-04-14 2022-04-14

   
Records found: 1312
  Page 8 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-09-19 4 OE $11.05 $110,500 D/D 10,000 53,266     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-09-16 4 AS $73.08 $146,163 I/I (2,000) 48,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-09-16 4 OE $12.99 $25,980 I/I 2,000 50,740     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-09-10 4 A $70.06 $1,053 D/D 15 68,732     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-09-09 4 AS $73.00 $1,460,000 D/D (20,000) 62,262     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-09-09 4 OE $21.51 $430,200 D/D 20,000 82,262     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-09-05 4 AS $70.00 $700,000 D/D (10,000) 43,266     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-09-05 4 OE $11.05 $110,500 D/D 10,000 53,266     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-09-04 4 AS $69.00 $621,000 D/D (9,000) 37,950     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-09-04 4 OE $39.06 $351,540 D/D 9,000 46,950     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-08-15 4 S $64.36 $64,364 I/I (1,000) 48,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-08-15 4 OE $12.99 $12,990 I/I 1,000 49,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-07-15 4 OE $63.70 $63,698 I/I 1,000 48,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-07-15 4 OE $12.99 $12,990 I/I 1,000 49,740     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-07-01 4 AS $59.56 $243,063 D/D (4,066) 37,950     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-07-01 4 AS $60.00 $600,000 D/D (10,000) 43,266     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-07-01 4 OE $11.05 $110,500 D/D 10,000 53,266     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-06-19 4 A $58.57 $1,057 D/D 18 68,717     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-12 4 OE $12.99 $64,950 I/I 5,000 48,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-05 4 OE $58.68 $593,406 I/I 10,000 43,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-05 4 OE $12.99 $129,900 I/I 10,000 53,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-04 4 OE $60.72 $607,194 I/I 10,000 43,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-04 4 OE $12.99 $129,900 I/I 10,000 53,740     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-06-03 4 AS $58.32 $64,036 D/D (1,098) 43,266     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-06-03 4 AS $58.34 $28,763 D/D (493) 14,880     -
  1312 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us